08048035968
ELEFTHA 440MG Injection wholesale and global supplier from India to Australia | Phoenix Exim.

1. General Information

  • Brand: Eleftha 440mg Injection
  • Active ingredient: Trastuzumab
  • Strength: 440mg
  • Drug class: HER2-targeted monoclonal antibody
  • Dosage form: Injectable/lyophilized powder for intravenous infusion
  • Manufacturer: Intas Pharmaceuticals Ltd.
  • Prescription: Required
  • Storage: Refrigerated at 2°C–8°C; do not freeze.

Eleftha is intended for use under the supervision of an oncologist or other appropriately qualified healthcare professional.

2. Product Information

Eleftha 440mg contains trastuzumab, which specifically targets the HER2 (human epidermal growth factor receptor 2) protein. HER2 can be overexpressed in some cancer cells and can contribute to abnormal cancer-cell growth.

The 440mg presentation is supplied as a vial and is administered by intravenous infusion after appropriate preparation by healthcare professionals. The exact regimen depends on the cancer type, treatment combination, patient's body weight, and the oncologist's treatment protocol.

3. Uses of Eleftha 440mg Injection

Eleftha may be prescribed for:

  • HER2-positive breast cancer
  • HER2-positive metastatic breast cancer
  • HER2-positive gastric cancer
  • HER2-positive gastroesophageal-junction adenocarcinoma

It may be used alone or together with chemotherapy or other anticancer treatments, depending on the patient's clinical condition and treatment plan. HER2 status is generally confirmed through appropriate diagnostic testing before treatment.

4. Benefits of This Medicine

The principal benefit of trastuzumab therapy is its targeted action against HER2-positive cancer cells.

Potential treatment benefits include:

  • Helps inhibit HER2-mediated cancer-cell growth.
  • May slow progression of HER2-positive cancers.
  • Can be incorporated into treatment regimens for breast and gastric cancers.
  • May help improve disease control when used according to an appropriate oncology treatment plan.

The expected benefit varies considerably between patients and depends on cancer stage, HER2 status, previous treatment and combination therapy.

5. Side Effects of Eleftha 440mg Injection

Trastuzumab can cause side effects, ranging from mild to potentially serious. Important adverse reactions can include:

  • Infusion-related reactions
  • Fever and chills
  • Headache
  • Nausea or vomiting
  • Diarrhea
  • Fatigue
  • Cough
  • Rash
  • Infections
  • Reduced blood-cell counts
  • Swelling/edema
  • Heart-related problems
  • Lung-related complications
  • Serious allergic or hypersensitivity reactions

Trastuzumab can potentially cause cardiac dysfunction, so heart function may need to be assessed before and during treatment.

6. Common Side Effects

Some commonly reported effects include:

  • Headache
  • Nausea
  • Fever
  • Chills
  • Fatigue
  • Diarrhea
  • Rash
  • Cough
  • Vomiting
  • Insomnia
  • Infection
  • Muscle or back pain

Not every patient experiences these effects. Any persistent, severe or unusual symptom should be reported to the treating healthcare professional.

7. How to Use Eleftha 440mg Injection

Eleftha should not be self-administered.

It is prepared and administered as an intravenous infusion by a qualified healthcare professional. The dose and frequency are determined by the oncologist according to the patient's body weight, cancer type, treatment regimen and response.

A commonly used trastuzumab regimen involves a weight-based loading dose followed by maintenance doses, but the exact regimen must be determined by the treating oncologist and should not be calculated or changed by the patient.

The medicine should be appropriately reconstituted and prepared under sterile conditions before administration.

8. How Eleftha 440mg Works

Eleftha contains trastuzumab, which binds specifically to the HER2 receptor on the surface of HER2-positive cancer cells.

This targeted binding interferes with HER2 signaling involved in cancer-cell growth and survival. It can also help the immune system recognize and attack targeted cancer cells. Consequently, trastuzumab can help slow cancer growth and progression.

9. Safety Advice

Prescription only: Use only under an oncologist's supervision.

Heart conditions: Inform the doctor about previous or existing heart problems. Cardiac monitoring may be necessary because trastuzumab can affect heart function.

Pregnancy: Trastuzumab may cause fetal harm. Tell your doctor if you are pregnant, planning pregnancy or could become pregnant.

Breastfeeding: Breastfeeding is generally not recommended during trastuzumab treatment and for the appropriate period afterward as advised by the treating physician.

Lung problems: Inform the healthcare team about existing lung disease or breathing problems.

Infusion reactions: Patients should be monitored during and after infusion, particularly during initial treatment.

Storage: Keep refrigerated at 2°C–8°C and do not freeze. Appropriate cold-chain handling is important.

Drug interactions: Tell your doctor about all medicines, chemotherapy, biologic treatments and supplements you are taking.

10. Frequently Asked Questions

Q1. What is Eleftha 440mg Injection?
Eleftha 440mg is a trastuzumab-containing targeted anticancer medicine used for certain HER2-positive cancers.

Q2. What is the generic name of Eleftha 440mg?
The active ingredient is trastuzumab 440mg.

Q3. What cancers can Eleftha treat?
It is used for appropriate patients with HER2-positive breast cancer and HER2-positive gastric or gastroesophageal-junction cancer.

Q4. Can Eleftha 440mg be self-injected?
No. It is administered by a qualified healthcare professional as an IV infusion.

Q5. Does Eleftha require refrigeration?
Yes. Product information specifies refrigerated storage at 2°C–8°C and advises not to freeze it.

Q6. Is Eleftha available by prescription?
Yes. It is a prescription medicine.

Q7. Can Eleftha be used during pregnancy?
Trastuzumab can cause fetal harm, so pregnancy status and contraception should be discussed with the treating physician before and during treatment.

Q8. What should I do if I experience breathing difficulty or severe swelling during treatment?
Seek immediate medical attention and inform the treating healthcare team, as severe infusion reactions, lung complications or cardiac problems can require urgent assessment.

11. Substitutes for Eleftha 440mg

Possible alternatives containing trastuzumab may include other trastuzumab brands/biosimilars, depending on the country and availability.

Examples may include:

  • Kintsugi 440mg Injection
  • HerMab 440mg Injection
  • Other locally approved trastuzumab products

A substitute should not be selected solely on the basis of the same strength. The oncologist or pharmacist should confirm that the alternative is appropriate for the patient's treatment. A current medicine listing identifies Kintsugi 440mg as a same-composition alternative to Eleftha 440mg.

12. SEO & B2B Keywords

  • Eleftha 440mg Injection exporter from India
  • Eleftha 440mg Injection supplier
  • Eleftha 440mg Trastuzumab Injection exporter
  • Eleftha 440mg Injection wholesale supplier
  • Eleftha 440mg Injection manufacturer India
  • Trastuzumab 440mg Injection exporter
  • Trastuzumab 440mg wholesale supplier India
  • Eleftha 440mg Injection supplier from Nagpur
  • Eleftha 440mg Injection pharmaceutical exporter India
  • Eleftha 440mg Injection international supplier
  • HER2 positive cancer medicine supplier
  • Trastuzumab Injection pharmaceutical exporter
  • Eleftha 440mg Injection for breast cancer
  • Eleftha 440mg Injection for gastric cancer
  • Eleftha 440mg Injection global supplier
  • Eleftha 440mg Injection export from India
  • Eleftha 440mg Injection supplier USA
  • Eleftha 440mg Injection supplier UK
  • Eleftha 440mg Injection supplier Australia
  • Eleftha 440mg Injection supplier Canada
  • Eleftha 440mg Injection supplier Singapore
  • Eleftha 440mg Injection supplier South Korea
  • Eleftha 440mg Injection supplier UAE
  • Trastuzumab 440mg oncology medicine exporter
  • Phoenix Exim pharmaceutical exporter Nagpur India
Aug 22nd, 2026 1:03 PM

Keywords